Compare Stocks: ANEB, BKHA, MREO, and TCRT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$0.32 +6.7%	$0.35	$0.00 ▼ $2.90	$13.05M	-1.82	33,746 shs	1,079 shs
BKHA Black Hawk Acquisition	$11.90 +1.0%	$12.24	$10.93 ▼ $13.10	$48.93M	0.04	1,079 shs	1,802 shs
MREO Mereo BioPharma Group	$0.32 +3.6%	$0.31	$0.20 ▼ $2.37	$49.11M	0.36	9.56 million shs	1.83 million shs
TCRT Alaunos Therapeutics	$1.93 -3.0%	$2.06	$1.67 ▼ $4.59	$48.60M	-1	9,252 shs	11,146 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+6.67%	+5.12%	+79,900.00%	-30.43%	-86.67%
BKHA Black Hawk Acquisition	+0.08%	+0.13%	-14.76%	+0.17%	+8.58%
MREO Mereo BioPharma Group	+3.64%	+7.63%	-2.74%	+32.05%	-81.57%
TCRT Alaunos Therapeutics	-3.02%	-3.02%	-9.39%	-21.86%	-19.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$0.32 +6.7%	$0.35	$0.00 ▼ $2.90	$13.05M	-1.82	33,746 shs	1,079 shs
BKHA Black Hawk Acquisition	$11.90 +1.0%	$12.24	$10.93 ▼ $13.10	$48.93M	0.04	1,079 shs	1,802 shs
MREO Mereo BioPharma Group	$0.32 +3.6%	$0.31	$0.20 ▼ $2.37	$49.11M	0.36	9.56 million shs	1.83 million shs
TCRT Alaunos Therapeutics	$1.93 -3.0%	$2.06	$1.67 ▼ $4.59	$48.60M	-1	9,252 shs	11,146 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+6.67%	+5.12%	+79,900.00%	-30.43%	-86.67%
BKHA Black Hawk Acquisition	+0.08%	+0.13%	-14.76%	+0.17%	+8.58%
MREO Mereo BioPharma Group	+3.64%	+7.63%	-2.74%	+32.05%	-81.57%
TCRT Alaunos Therapeutics	-3.02%	-3.02%	-9.39%	-21.86%	-19.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	1.00	Sell	N/A	N/A
BKHA Black Hawk Acquisition	1.00	Sell	N/A	N/A
MREO Mereo BioPharma Group	2.25	Hold	$3.25	919.13% Upside
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ANEB, BKHA, MREO, and TCRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	MREO Mereo BioPharma Group	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1.00
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BKHA Black Hawk Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/2/2026	MREO Mereo BioPharma Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/10/2026	MREO Mereo BioPharma Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/29/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/15/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.28 per share	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	$0.18 per share	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	$0.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.48M	-$0.19	N/A	N/A	N/A	N/A	-74.57%	-68.96%	9/23/2026 (Estimated)
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	-$41.88M	-$0.04	N/A	N/A	N/A	N/A	-74.82%	-64.28%	N/A
TCRT Alaunos Therapeutics	-$4.18M	-$2.13	N/A	N/A	N/A	N/A	-165.94%	-123.50%	8/18/2026 (Estimated)

Latest ANEB, BKHA, MREO, and TCRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A
8/11/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	-$0.01	N/A	-$0.05	$3.50 million	N/A
7/15/2026	Q2 2026	BKHA Black Hawk Acquisition	N/A	$0.02	N/A	$0.02	N/A	N/A
5/15/2026	Q1 2026	TCRT Alaunos Therapeutics	N/A	-$0.59	N/A	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BKHA Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	6.24	6.24
BKHA Black Hawk Acquisition	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	5.88	6.48
TCRT Alaunos Therapeutics	N/A	1.63	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
BKHA Black Hawk Acquisition	N/A
MREO Mereo BioPharma Group	62.83%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
BKHA Black Hawk Acquisition	N/A
MREO Mereo BioPharma Group	6.50%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	40.79 million	7.91 million	Not Optionable
BKHA Black Hawk Acquisition	N/A	4.15 million	N/A	N/A
MREO Mereo BioPharma Group	40	159.62 million	149.24 million	Optionable
TCRT Alaunos Therapeutics	40	24.42 million	20.48 million	No Data

ANEB, BKHA, MREO, and TCRT Headlines

Recent News About These Companies

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, BKHA, MREO, and TCRT Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$0.32 +0.02 (+6.67%)

As of 08/14/2026 03:35 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Black Hawk Acquisition NASDAQ:BKHA

$11.90 +0.12 (+1.02%)

As of 08/14/2026 04:00 PM Eastern

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Mereo BioPharma Group NASDAQ:MREO

$0.32 +0.01 (+3.64%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.30 -0.01 (-4.67%)

As of 08/14/2026 07:47 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Alaunos Therapeutics NASDAQ:TCRT

$1.93 -0.06 (-3.02%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.13 (+6.74%)

As of 08/14/2026 07:55 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANEB, BKHA, MREO, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANEB, BKHA, MREO, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANEB, BKHA, MREO, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, BKHA, MREO, and TCRT Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

Black Hawk Acquisition NASDAQ:BKHA

Mereo BioPharma Group NASDAQ:MREO

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANEB, BKHA, MREO, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANEB, BKHA, MREO, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANEB, BKHA, MREO, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, BKHA, MREO, and TCRT Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

Black Hawk Acquisition NASDAQ:BKHA

Mereo BioPharma Group NASDAQ:MREO

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools